n as a possible biomarker to improve treatment and patient outcomes in multiple myeloma," said senior author Keith Stewart, MD, Professor of Medicine in the Division of Hematology-Oncology at Mayo Clinic in Scottsdale, Ariz. "This work also suggests that we can begin to isolate the cause of birth defects from the anti-cancer properties in order to develop safer drugs in the future."
Yuan Xiao Zhu, PhD, will present this study in an oral presentation on Sunday, December 11, at 4:30 p.m. PST at the San Diego Convention Center in Room 6DE.
Final Analysis of a Randomized Comparison of ABVD Chemotherapy with a Strategy that Includes Radiation Therapy (RT) in Patients with Limited-Stage Hodgkin Lymphoma (HL): NCIC CTG/ECOG HD.6 [Abstract 590]
New research concludes that patients with limited-stage Hodgkin lymphoma treated with a standard chemotherapy regimen have better overall survival rates compared with those receiving a radiation-based treatment.
Patients with limited-stage Hodgkin lymphoma (HL) are often treated with combination therapy containing chemotherapy plus radiation (RT). While this therapy is successful in controlling HL, these patients remain challenged by potential long-term complications of radiation exposure such as heart conditions or subsequent cancers.
To determine if HL patients treated with standard chemotherapy (ABVD) have better long-term survival than those treated with radiation-based therapy, researchers from Canada's NCIC Clinical Trials Group (NCIC CTG) designed a trial comparing the 12-year overall survival (OS) between the two groups. The Eastern Cooperative Oncology Group (ECOG) also participated in the trial. Along with overall survival, the trial also examined secondary survival factors, including freedom from disease progression (FFDP) and event-free survival (EFS).
Approximately 400 patients with no
Page: 1 2 3 4 5 6 7 8 9 Related biology technology :1
|SOURCE American Society of Hematology|
Copyright©2010 PR Newswire.
All rights reserved
. Established and Emerging Biotech Clusters2
. PAREXEL International to Present at Robert Baird Healthcare Conference and William Blair Emerging Growth Stock Conference3
. Tumor Marker Diagnostic Technologies: Assessment of Current and Emerging Technologies, And Their Potential Market Applications4
. GRAPHENE-CA appointed an EU Future Emerging Technology flagship pilot5
. Reportlinker Adds Top & Emerging Bio-Fuel Markets by Technology, Feedstocks, Regulations, Pricing & Commercialization Trends & Forecasts (2011 - 2016)6
. Reportlinker Adds The 2011 Blood Banking Market: US, Europe, Japan - Emerging Opportunities and Business Expansion Strategies for Suppliers7
. Zimmer Helps Physicians and Hospitals Negotiate Emerging Health Care Business Challenges Through New Consulting Programs8
. Elixir Bio-Tech Inc. Elected One of Top 50 Emerging Companies by 100 Venture Capital Funds & Angel Investors9
. Reportlinker Adds Future US In Vitro Diagnostics Market: Strategic Implications of Emerging Reimbursement, Technological and Market Trends Through 201810
. Reportlinker Adds The 2011 Coagulation Testing Market: US, Europe, Japan Emerging Business Opportunities and Market Expansion Strategies for Suppliers11
. Reportlinker Adds Emerging Opportunities in Biosimilar and Biobetter Drugs Markets